$SYRE
Spyre Therapeutics, Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017009615 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $982.0K $859.0K
YoY Change 14.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.360M $1.830M
YoY Change 28.96% 115.29%
% of Gross Profit
Research & Development $4.949M $3.596M
YoY Change 37.63% 121.7%
% of Gross Profit
Depreciation & Amortization $52.00K $29.00K
YoY Change 79.31% 70.59%
% of Gross Profit
Operating Expenses $7.313M $5.426M
YoY Change 34.78% 119.77%
Operating Profit -$6.331M -$4.567M
YoY Change 38.62% 84.97%
Interest Expense $100.0K $30.00K
YoY Change 233.33%
% of Operating Profit
Other Income/Expense, Net $84.00K $20.00K
YoY Change 320.0% 1900.0%
Pretax Income -$6.250M -$4.550M
YoY Change 37.36% 84.21%
Income Tax
% Of Pretax Income
Net Earnings -$6.247M -$4.547M
YoY Change 37.39% 84.24%
Net Earnings / Revenue -636.15% -529.34%
Basic Earnings Per Share
Diluted Earnings Per Share -$467.5K -$398.1K
COMMON SHARES
Basic Shares Outstanding 13.45M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $57.90M $29.00M
YoY Change 99.66% -33.79%
Cash & Equivalents $16.80M $24.02M
Short-Term Investments $41.10M $5.000M
Other Short-Term Assets $1.500M $4.600M
YoY Change -67.39% 1050.0%
Inventory
Prepaid Expenses
Receivables $1.000M $1.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $60.30M $35.20M
YoY Change 71.31% -20.18%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $300.0K
YoY Change 166.67% 50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $0.00
YoY Change
Total Long-Term Assets $1.000M $300.0K
YoY Change 233.33% 0.0%
TOTAL ASSETS
Total Short-Term Assets $60.30M $35.20M
Total Long-Term Assets $1.000M $300.0K
Total Assets $61.30M $35.50M
YoY Change 72.68% -20.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $500.0K
YoY Change -40.0% 66.67%
Accrued Expenses $3.600M $3.300M
YoY Change 9.09% 266.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.000M $3.800M
YoY Change 5.26% 216.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $0.00
YoY Change
Total Long-Term Liabilities $100.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.000M $3.800M
Total Long-Term Liabilities $100.0K $0.00
Total Liabilities $4.100M $3.800M
YoY Change 7.89% 216.67%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $57.20M $31.70M
YoY Change
Total Liabilities & Shareholders Equity $61.30M $35.50M
YoY Change 72.68% -20.05%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$6.247M -$4.547M
YoY Change 37.39% 84.24%
Depreciation, Depletion And Amortization $52.00K $29.00K
YoY Change 79.31% 70.59%
Cash From Operating Activities -$5.430M -$3.990M
YoY Change 36.09% 60.89%
INVESTING ACTIVITIES
Capital Expenditures $271.0K $2.000K
YoY Change 13450.0% -80.0%
Acquisitions
YoY Change
Other Investing Activities -$25.34M -$1.190M
YoY Change 2029.41% 11800.0%
Cash From Investing Activities -$25.61M -$1.190M
YoY Change 2052.1% 5850.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K -100.0K
YoY Change -200.0% -100.23%
NET CHANGE
Cash From Operating Activities -5.430M -3.990M
Cash From Investing Activities -25.61M -1.190M
Cash From Financing Activities 100.0K -100.0K
Net Change In Cash -30.94M -5.280M
YoY Change 485.98% -112.82%
FREE CASH FLOW
Cash From Operating Activities -$5.430M -$3.990M
Capital Expenditures $271.0K $2.000K
Free Cash Flow -$5.701M -$3.992M
YoY Change 42.81% 60.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4949000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
7313000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6331000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
95000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
84000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-6247000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13365823
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-33000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6280000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3596000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2364000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1830000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5426000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4567000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
26000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-4547000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.10
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
640699
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4543000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2017Q1 agle Payment For Premium On Investments
PaymentForPremiumOnInvestments
55000
CY2016Q1 agle Payment For Premium On Investments
PaymentForPremiumOnInvestments
16000
CY2017Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
49000
CY2017Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-5000
CY2017Q1 agle Amortization Of Lease Allowance Liability
AmortizationOfLeaseAllowanceLiability
10000
CY2016Q1 agle Amortization Of Lease Allowance Liability
AmortizationOfLeaseAllowanceLiability
6000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
140000
CY2016Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
20000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-234000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-79000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-151000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
431000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
95000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
261000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-87000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
475000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5432000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3988000
CY2016Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
8000
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41104000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
271000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32780000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2940000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7440000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1750000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25611000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1192000
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
98000
CY2017Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
96000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
96000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-98000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30947000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5278000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29294000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24016000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include those related to accruals of research and development related costs, fair values of preferred and common stock, stock-based compensation, and certain company income tax related items. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p></div>
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company&#8217;s investment policy limits investments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks, subject to certain concentration limits and restrictions on maturities. The Company&#8217;s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and bond issuers.</p></div>
CY2017Q1 agle Working Capital
WorkingCapital
56300000
CY2017Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain reclassifications have been made to prior period amounts to conform to current period presentation. These reclassifications did not have an impact on the Company&#8217;s results of operations or financial position as of March 31, 2017 and December 31, 2016.</p></div>
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1270000
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
57900000
CY2017Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2017Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
510000000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q1 agle Number Of Subsidiary Corporations Owned
NumberOfSubsidiaryCorporationsOwned
7
CY2017Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14031000
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
14031000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
37000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41067000
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
43834000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43834000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15758000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15754000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
39075000
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
15754000
CY2017Q1 agle Available For Sale Securities Debt Maturities Year One Through Two Fair Value
AvailableForSaleSecuritiesDebtMaturitiesYearOneThroughTwoFairValue
1992000
CY2017Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
759000
CY2017Q1 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2022000
CY2016Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1749000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
743000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
480000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
227000
CY2017Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
55098000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
59588000
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
39000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
314000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
283000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
291000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
300000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1188000
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
76000
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
35000

Files In Submission

Name View Source Status
0001564590-17-009615-index-headers.html Edgar Link pending
0001564590-17-009615-index.html Edgar Link pending
0001564590-17-009615.txt Edgar Link pending
0001564590-17-009615-xbrl.zip Edgar Link pending
agle-10q_20170331.htm Edgar Link pending
agle-20170331.xml Edgar Link completed
agle-20170331.xsd Edgar Link pending
agle-20170331_cal.xml Edgar Link unprocessable
agle-20170331_def.xml Edgar Link unprocessable
agle-20170331_lab.xml Edgar Link unprocessable
agle-20170331_pre.xml Edgar Link unprocessable
agle-ex101_287.htm Edgar Link pending
agle-ex311_65.htm Edgar Link pending
agle-ex312_66.htm Edgar Link pending
agle-ex321_67.htm Edgar Link pending
agle-ex322_68.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending